TransMedics Group Signals Strong Growth in Earnings Call

Transmedics Group ((TMDX)) has held its Q4 earnings call. Read on for the main highlights of the call.

TransMedics Group’s latest earnings call struck an optimistic tone, underscoring powerful revenue momentum, widening operating margins and a fortified balance sheet even as management flagged some near-term pressures. Executives emphasized that accelerating adoption of the Organ Care System, especially in liver and heart, is reshaping U.S. transplant volumes and providing a durable growth runway despite margin headwinds and trial-related risks.

Strong Revenue Growth (Q4 and Full Year 2025)

TransMedics delivered Q4 2025 revenue of about $161M, up roughly 32% year over year and 12% sequentially, highlighting accelerating demand for its organ preservation ecosystem. Full-year revenue climbed to $605.5M, a robust 37% increase versus 2024, confirming that the company is scaling rapidly from a niche technology provider into a mainstream transplant platform player.

Improved Profitability and Operating Leverage

Profitability improved sharply as scale kicked in, with 2025 operating profit reaching about $108.6M, or 18% of revenue, more than doubling the prior year’s 8.5% margin. Q4 operating profit of roughly $21.3M, or 13.2% of sales, shows that while margins can fluctuate quarter to quarter, the broader trend is toward stronger operating leverage as volumes grow.

Strong Cash Position

The company closed 2025 with about $488.4M in cash and equivalents, up $22M from the prior quarter, giving it significant financial flexibility. Management highlighted that this cash stack supports continued investment in R&D, clinical trials and global infrastructure build-out while preserving strategic optionality for future initiatives.

Large Increase in OCS Clinical Volume and Market Impact

Total U.S. OCS transplants surged to 5,139 in 2025 from 3,735 in 2024, moving the platform to roughly 26% share of U.S. liver, heart and lung transplants. The company argued that U.S. transplant volumes for these organs have risen 25% since 2022 with OCS, and would have actually declined slightly without its technology, spotlighting OCS as a key structural growth driver for the broader transplant market.

Organ-Level Adoption — Liver and Heart Momentum

Liver remained the standout, with 4,197 OCS Liver cases in 2025 representing about 36% of U.S. liver transplants, up from 26% in 2024, indicating rapid penetration of this franchise. OCS Heart also grew, with 854 cases equating to roughly 18% of heart transplants, modestly higher than 17%, showing steady but less explosive adoption relative to liver.

Product and Service Revenue Strength

Q4 product revenue came in around $100M, up 34% year over year and 15% sequentially, while service revenue reached roughly $60M, rising 29% and 8%, respectively. For the full year, product revenue totaled $372M and service revenue $233M, underscoring that both consumables and services are scaling in tandem and reinforcing the recurring nature of the model.

Logistics and Operational Expansion

TransMedics’ transplant logistics arm continued to expand, with Q4 logistics service revenue at about $28.6M, up 32% year over year and 5% sequentially. The company ended 2025 operating 22 aircraft and covering roughly 80% of missions requiring air transport, up from 75%, reflecting vertical integration designed to support reliability and speed for transplant centers.

International Progress and Guidance

International revenue remained small but showed accelerating signs, with Q4 contributions of about $4.8M, up 24% year over year and 33% sequentially, and full-year revenue of $16.7M, up 9.3%. Management paired these early gains with a 2026 revenue outlook of $727M to $757M, implying 20%–25% growth and a long-term gross margin goal around 60%, though they acknowledged that international build-out will weigh on margins near term.

Pipeline and Platform Investments

The company is investing heavily in clinical and platform programs, including ENHANCE Heart Parts A and B, the DENOVO Lung trial, an OCS Kidney system and a next-generation OCS Gen 3.0 platform. Executives framed these initiatives as critical growth engines that should sustain momentum over the near, medium and long term by expanding indications, organs and platform capabilities.

Q4 Gross Margin Pressure and Inventory/Freight Costs

Q4 total gross margin slipped to about 58%, down roughly 110 basis points year over year and 70 basis points sequentially, highlighting some pressure beneath the headline growth. Management cited higher clinical service costs, increased logistics discounts, elevated freight expenses and year-end inventory charges as the main drivers, but positioned these as manageable as scale improves.

Net Income Boosted by One-Time Tax Benefit

Reported profitability was flattered by a significant one-off tax gain, with Q4 net income of $105M and full-year net income of $190M including an $83.8M income tax benefit from a valuation allowance release. Management made clear this is a non-recurring event and that investors should focus more on operating profit and cash generation as indicators of underlying performance.

Low OCS Lung Adoption

OCS Lung remains a modest contributor, with only 88 cases in 2025, or about 2% of lung transplant volume, well behind liver and heart adoption levels. The company stressed that meaningful growth from the lung franchise hinges on successful execution and adoption following the DENOVO trial, making this a potential upside lever rather than a current driver.

Clinical Trial Headwinds (ENHANCE Part B)

Progress on ENHANCE Heart Part B has been slower than hoped, as some providers and suppliers of competing static cold storage technologies have been reluctant to support head-to-head randomization. Management cautioned that these competitive dynamics could delay trial completion and the timing of potential new heart indications, introducing uncertainty into the clinical roadmap.

International Expansion and Execution Risk

TransMedics’ European rollout of its National OCS Program, starting with Italy, and broader international expansion are still at an early stage and require substantial logistics and clinical infrastructure. Executives acknowledged that this up-front investment may moderate near-term international revenue ramp and pressure margins until sufficient scale is achieved abroad.

Planned 2026 Investment and Near-Term Margin Compression

Looking ahead, the company plans to step up R&D and clinical spending in 2026 to advance ENHANCE, DENOVO, OCS Kidney and Gen 3.0, and said these investments will temporarily compress profitability. Operating margins are expected to be up to about 250 basis points below 2025 levels next year before resuming an expansion trajectory in subsequent years as the pipeline begins to pay off.

Seasonality and Operational Staffing Risks

Management flagged that U.S. transplant activity can exhibit Q3 seasonality, which may cause short-term volume softness even within a strong annual growth pattern. They also noted that ramping logistics and clinical staffing to match demand is essential, and any execution hiccups in hiring or training could affect the timing of growth and service quality.

Forward-Looking Guidance and Strategic Outlook

For 2026, TransMedics guided revenue to $727M–$757M, implying 20%–25% growth driven by higher OCS utilization, broader adoption and expanded service revenue, with similar seasonal patterns as in prior years. Management reiterated a long-run gross margin target near 60%, expects 2026 operating margins around 15.5% before climbing toward roughly 30% by 2028, plans continued R&D and Gen 3.0 investment, aims to complete the OCS Kidney trial by early 2027 and does not currently intend to expand its 22-jet fleet.

TransMedics’ earnings call painted a picture of a company transforming the transplant landscape while managing the growing pains of rapid scale. With strong revenue growth, rising clinical adoption and a deep pipeline offset by temporary margin compression, trial timing risks and execution challenges, investors are being asked to look through near-term noise to the long-term potential of a fully built-out multi-organ platform.